ABSTRACT
Background Latent TB infection (LTBI) screening and treatment of population groups at high risk for TB is part of England’s Tuberculosis Action Plan, which has succeeded in increasing testing volumes. However, analysis of the cost-effectiveness is hampered by a lack of detailed information on health service costs.
Methods We surveyed clinics with large volumes of activity, located in the London, West Midlands, South East & South West, and North West England TB Control Board areas. These represent three-quarters of England’s TB diagnoses. We mapped clinical pathways and determined costs of staff time, testing, and drugs.
Results The clinics use interferon gamma release assays (IGRAs) (Quantiferon-TB Gold Plus, T-SPOT.TB, or both) for LTBI testing, and the most common outcomes of the testing pathways are asymptomatic patients testing negative (costing £64.11 per patient, range: £49.08-£81.02) or positive (costing £142.86(£120.95-£174.68)). Symptomatic patients, testing positive or negative, have higher costs (£124.35(£101.29-£138.23)). The estimated cost per patient diagnosed with LTBI is £458.32(£362.49-£571.47). Treatment costs depend on the regimen and the amount of monitoring the patient requires, e.g. 3 months daily Isoniazid and Rifampicin costs £192.86(£140.43-£255.32) for most patients, and £238.62(£157.47-£346.03) for those requiring more monitoring. 6 months daily Isoniazid costs £407.71(£342.56-£474.25). 4 months daily Rifampicin costs £226.98(£190.16-£270.73). One clinic uses 3 months of weekly Isoniazid and Rifapentine for some patients, costing £559.05.
Discussion These are the first detailed cost estimates of latent TB screening and treatment, and will enable improved assessment of cost-effectiveness, and allocation of resources.
Competing Interest Statement
PJW has received payment from Pfizer for teaching of mathematical modeling of infectious disease transmission and vaccination, and from the Dutch National Institute for Public Health and the Environment (RIVM) for participation in an audit committee on COVID-19 data analytics and modeling. All other authors report no potential conflicts.
Funding Statement
This work was funded by NIHR Health Technology Assessment grant NIHR127459. It was also supported by the UK MRC Centre for Global Infectious Disease Analysis (grant number MR/X020258/1); this award comes under the Global Health EDCTP3 Joint Undertaking. Support also come from the NIHR Health Protection Research Unit in Modelling and Health Economics, which is a partnership between the UKHSA, Imperial College London, and the London School of Hygiene & Tropical Medicine (grant code NIHR200908). RKG is funded by National Institute for Health Research (NIHR303184) and by NIHR Biomedical Research Funding to UCL and UCLH. IA is funded by the European Union under grant agreement no. 101046314 and the UK National Institute for Health and Care Research (NIHR) under grant NF-SI-0616-10037. The funding sources had no involvement in study design, analysis and interpretation of data, writing of the report, or the decision to submit the article for publication. The views expressed are those of the authors and not necessarily those of the UK Department of Health and Social Care; Foreign, Commonwealth and Development Office; European Union; UK Medical Research Council (MRC); National Institute for Health and Care Research (NIHR); or UK Health Security Agency (UKHSA).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos